Viking Therapeutics reports wider loss: what it means for Viking Therapeutics stock

Published on 10/29/2026 at 14:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Third-quarter loss reached USD 183.2 million on September 30, 2026. Viking Therapeutics stock stood at EUR 22.13 on October 29, 2026.

Pipeline and financial position

Viking held USD 960 million in cash, cash equivalents and short-term investments on September 30, 2026.
Research and development expenses reached USD 166.8 million in the third quarter of 2026.
SUNRISE-1 and SUNRISE-2 each target enrollment of 560 adults in oral VK2735 studies.

VKTX, US92686J1060, Illustration mit AI erstellt.

Viking Therapeutics (ISIN US92686J1060) reported a USD 183.2 million net loss for the third quarter ended September 30, 2026, compared with USD 90.8 million a year earlier. The company also advanced oral and injectable Phase 3 programs for VK2735, according to Viking Therapeutics in its October 28, 2026 release.

Loss widens as development spending rises

Research and development expenses climbed to USD 166.8 million in the third quarter from USD 90.0 million in the prior-year period. General and administrative expenses also increased to USD 20.3 million from USD 8.6 million, reflecting the costs of larger clinical programs and preparations for a possible commercial launch.

The nine-month net loss reached USD 469.5 million through September 30, 2026, versus USD 202.0 million in the comparable 2025 period. Viking reported no revenue for either quarter because its drug candidates remain in development, while its cash, cash equivalents and short-term investments totaled USD 960 million at quarter-end, up from USD 706 million on December 31, 2025.

What does Phase 3 mean for VK2735?

The pipeline update is the operating counterweight to the wider loss. VANQUISH-1 and VANQUISH-2, testing weekly injectable VK2735, continued on track and are expected to be completed in 2027. SUNRISE-1 and SUNRISE-2, which test daily oral VK2735, each target 560 adults in 68-week studies, according to PR Newswire.

Three dated milestones frame the current setup. On October 6, 2026, Viking initiated an oral maintenance-dosing study. On October 14, 2026, it started the oral SUNRISE Phase 3 program with 560 adults targeted per study. On October 28, 2026, it reported the third-quarter loss and said the Phase 3 programs were advancing, all in the company's investor release.

Upcoming dates for investors

Viking's next visible research calendar includes the Stifel Healthcare Conference from November 10 through November 12, 2026, and ObesityWeek presentations from November 14 through November 17, 2026. The company also expects to complete its VK3019 single ascending dose study in the fourth quarter of 2026 and begin a multiple ascending dose study in the first quarter of 2027, according to Viking Therapeutics.

Stock quote in Germany

Viking Therapeutics stock was trading at EUR 22.13 at Lang & Schwarz on October 29, 2026 at 2:03 p.m. CEST. The primary listing is Nasdaq, where the stock last stood at USD 25.36 on October 28, 2026 at 4:00 p.m. ET.

The further course of trading is shown by the continuously updated real-time quote of Viking Therapeutics stock.